New Arzerra approval to ease pressure from competition
Genmab's leukemia drug Arzerra has been approved in the US in combination with two other drugs. The label expansion might ease some of the pressure from rivals to the oncology product, says an analyst.
BY LOUISE WENDT JENSEN & RITZAU FINANS
The announcement was not expected to come until September. But on the last day of August, Genmab announced to the Copenhagen stock market that the US FDA has granted approval of a supplemental Biologics License Application (sBLA) for the use of Arzerra in combination with fludarabine and cyclophosphamide (FC) for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL).
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Genmab's sclerosis hope takes big step forward
For abonnenter
Genmab’s Arzerra approved for extended use in CLL
For abonnenter
